Apr 03, 2018

Tmunity Appoints Jason Krentz as Chief Technology Officer and Head of Technical Operations

PHILADELPHIA, PA, April 3, 2018 – Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced the appointment of Jason Krentz as Chief Technology Officer and Head of Technical Operations. Mr. Krentz formerly served in manufacturing and technical operations leadership roles at Endo Pharmaceuticals, Auxilium Pharmaceuticals and Tengion.

“Jason brings a track record of successful leadership in life sciences manufacturing, supply chain and technology development, all invaluable skill sets to help us advance our pipeline of patient-specific therapies to treat cancer,” said Usman “Oz” Azam, MD, President and Chief Executive Officer of Tmunity. “I am delighted Jason is joining Tmunity at a critical time in our growth, and his appointment is one of many exciting milestones for us this year.”  

In his management role at Tmunity, Mr. Krentz will be responsible for all aspects of the company’s manufacturing and technical operations including development and leadership of key functions, including manufacturing sciences, process and analytical development, cGMP manufacturing operations, quality control and assurance and facilities management. He will also work closely with the staff at the University of Pennsylvania and external partners to identify, evaluate, develop and implement manufacturing process improvements, process automation and analytical technologies to improve manufacturing robustness and reliability. 

“Jason is a welcome addition to the Tmunity management team as his experience complements our clinical development goals to integrate the best technologies and pursue multiple approaches to engineered T cell therapies to transform the treatment of cancer and other devastating diseases,” said Bruce Levine, PhD, Scientific Founder of Tmunity and Founding Director of the Clinical Cell and Vaccine Production Facility in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. “We look forward to collaborating with Jason as we move our programs into the clinic.”

Mr. Krentz joins Tmunity from Endo Pharmaceuticals where he was responsible for biologic and specialty implant manufacturing, supply chain and process development operations. Prior to Endo, he was Vice President of Technical Operations and Head of CMC Project Management at Auxilium Pharmaceuticals (acquired by Endo), responsible for global manufacturing and supply chain, technical development and alliance management activities. Before joining Endo, Mr. Krentz was Head of Technical Operations at Tengion, a clinical stage developer of autologous regenerative medicine therapies. Earlier in his career, Mr. Krentz worked at Centocor/Johnson & Johnson where he held positions of increasing responsibility in process technical support roles and was head of upstream manufacturing operations at a large-scale mammalian cell culture facility.   

Mr. Krentz holds a Master of Business Administration degree from St. Joseph’s University and a Bachelor of Science degree in Materials Science and Engineering from the University of Michigan. 

About Tmunity Therapeutics


Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T cell medicine. The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body, with an initial focus in cancer with two programs currently in the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of its T cell therapies. For more information, visit www.tmunity.com.


# # #


Media Contact:

Mike Beyer

Sam Brown Inc. Healthcare Communications